BioNexus Gene Lab Corp
For the period ended Dec 31, 2023. Filed Apr 16, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 16, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| BioNexus Gene Lab Corporation | |
|---|---|
| /s/ Su-Leng Tan Lee | Dated: April 16, 2024 |
| Su-Leng Tan Lee | |
| Chief Executive Officer | |
| (Principal Executive Officer) | |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| /s/ Su-Leng Tan Lee | Dated: April 16, 2024 |
|---|---|
| Su-Leng Tan Lee | |
| Chief Executive Officer and Director | |
| (Principal Executive Officer) | |
| /s/ Su-Leng Tan Lee | Dated: April 16, 2024 |
| Su-Leng Tan Lee | |
| Acting Chief Financial Officer | |
| (Principal Financial and Accounting Officer) | |
| /s/ Chee Keong Yap | Dated: April 16, 2024 |
|---|---|
| Chee Keong Yap | |
| Director | |
| /s/ Koon Wai Wong | Dated: April 16, 2024 |
| Koon Wai Wong | |
| Director | |
| /s/ Muhammad Azrul bin Abdul Hamid | Dated: April 16, 2024 |
|---|---|
| Muhammad Azrul bin Abdul Hamid | |
| Director | |
| PART I FINANCIAL INFORMATION | Page | ||
|---|---|---|---|
| ITEM FINANCIAL STATEMENTS: | |||
| 1. | |||
| Audit Report | F-2-F-3 | ||
| Consolidated Balance Sheets as of December 31, 2023 and 2022 | F-4 to F-5 | ||
| Consolidated Statement of Operations and Comprehensive Income/(Loss) for the Year Ended December 31, 2023 and 2022 | F-6 | ||
| Consolidated Statement of Changes in Stockholders’ Equity for the Year Ended December 31, 2023 and 2022 | F-7 | ||
| Consolidated Statement of Cash Flows for the Year Ended December 31, 2023 and 2022 | F-8 to F-9 | ||
| Notes to the Consolidated Financial Statements | F-10 to F-23 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.